Taken together, their expression of checkpoint receptors, their strategic location in close tumor contact and their ability to proliferate in situ after a local stimulus suggest that TRM cells are enriched in tumor-specific CD8+ T cells, making them possible effectors of anti-PD-1/anti-PD-L1 cancer immunotherapy. The gene discussed is CD8A; the disease is neoplasm.